400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Neuronal Signaling / Dopamine Receptor / GSK163090
CAS No.: 844903-58-8
Synonyms: N/A
GSK163090 is a potent, selective, and orally active 5-HT1A/B/D receptor antagonist with pKi of 9.4/8.5/9.7, and 6.3/6.7 for dopamine D2/D3, respectively.
生物活性
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT00896363 | Depressive Disorder | Phase 2 | Completed | - | Russian Federation ... more >> GSK Investigational Site Ekaterinburg, Russian Federation, 620030 GSK Investigational Site Kemerovo, Russian Federation, 650036 GSK Investigational Site Lipetsk Region, Russian Federation, 399083 GSK Investigational Site Moscow, Russian Federation, 119992 GSK Investigational Site Nizhny Novgorod, Russian Federation, 603107 GSK Investigational Site Saint Petersburg, Russian Federation, 190005 GSK Investigational Site Saint Petersburg, Russian Federation, 191180 GSK Investigational Site Saint-Petersburg, Russian Federation GSK Investigational Site Saratov, Russian Federation, 410060 GSK Investigational Site Smolensk, Russian Federation, 214 019 GSK Investigational Site St-Petersburg, Russian Federation, 197341 GSK Investigational Site St. Petersburg, Russian Federation, 190121 GSK Investigational Site St. Petersburg, Russian Federation, 194044 GSK Investigational Site St.Petersburg, Russian Federation, 193167 GSK Investigational Site Tomsk, Russian Federation, 634014 Collapse << |
NCT00435695 | Healthy Subjects ... more >> Depressive Disorder and Anxiety Disorders Collapse << | Phase 1 | Completed | - | Canada, Ontario ... more >> GSK Investigational Site Toronto, Ontario, Canada, M5T 1R8 Collapse << |
NCT00896363 | - | - | Completed | - | - |
实验方案
技术信息
CAS号 | 844903-58-8 | 储存条件 |
|
|
分子式 | C25H29N5O | 运输 | 蓝冰 | |
分子量 | 415.53 | 别名 | N/A |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT00896363 | Depressive Disorder | Phase 2 | Completed | - | Russian Federation ... more >> GSK Investigational Site Ekaterinburg, Russian Federation, 620030 GSK Investigational Site Kemerovo, Russian Federation, 650036 GSK Investigational Site Lipetsk Region, Russian Federation, 399083 GSK Investigational Site Moscow, Russian Federation, 119992 GSK Investigational Site Nizhny Novgorod, Russian Federation, 603107 GSK Investigational Site Saint Petersburg, Russian Federation, 190005 GSK Investigational Site Saint Petersburg, Russian Federation, 191180 GSK Investigational Site Saint-Petersburg, Russian Federation GSK Investigational Site Saratov, Russian Federation, 410060 GSK Investigational Site Smolensk, Russian Federation, 214 019 GSK Investigational Site St-Petersburg, Russian Federation, 197341 GSK Investigational Site St. Petersburg, Russian Federation, 190121 GSK Investigational Site St. Petersburg, Russian Federation, 194044 GSK Investigational Site St.Petersburg, Russian Federation, 193167 GSK Investigational Site Tomsk, Russian Federation, 634014 Collapse << |
NCT00435695 | Healthy Subjects ... more >> Depressive Disorder and Anxiety Disorders Collapse << | Phase 1 | Completed | - | Canada, Ontario ... more >> GSK Investigational Site Toronto, Ontario, Canada, M5T 1R8 Collapse << |
NCT00896363 | - | - | Completed | - | - |
NCT00559299 | Depressive Disorder, Major ... more >> Major Depressive Disorder (MDD) Collapse << | Phase 1 | Completed | - | United States, Kansas ... more >> GSK Investigational Site Wichita, Kansas, United States, 67211 Collapse << |
NCT00536679 | Depressive Disorder and Anxiet... more >>y Disorders Collapse << | Phase 1 | Completed | - | Germany ... more >> GSK Investigational Site Neuss, Nordrhein-Westfalen, Germany, 41460 Collapse << |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网